Zealand Pharma
1
63M
1
0.04
- Areas of investment
Summary
Zealand Pharma is the famous Corporate Investor, which was founded in 1998. The company was established in Europe in Denmark. The leading representative office of defined Corporate Investor is situated in the Copenhagen.
The fund is constantly included in less than 2 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2019.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Medical Device, Artificial Intelligence. Among the various public portfolio startups of the fund, we may underline Beta Bionics Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Zealand Pharma, startups are often financed by Novo Nordisk, RTW Investments LLC, Eventide Asset Management. The meaningful sponsors for the fund in investment in the same round are RTW Investments LLC, Eventide Asset Management, Dexcom.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.04
- Investments by industry
- Medical Device (1)
- Biotechnology (1)
- Diabetes (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Beta Bionics | 10 Jan 2019 | Biotechnology, Medical Device, Diabetes | Early Stage Venture | 63M | United States, Massachusetts, Boston |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.